title: Immunotherapy Slows TNBC Progression.
abstract: The experimental monoclonal antibody MPDL3280A extended progression-free survival and produced durable responses in some patients with triple-negative breast cancer, according to preliminary results from a phase I trial.
mesh_terms: D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D017321:Clinical Trials, Phase I as Topic; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D016896:Treatment Outcome; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C000594389:atezolizumab